Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA

Reuters03-25

Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA

Shanghai Bao Pharmaceuticals said the Phase III trial of KJ103 as desensitization therapy for highly sensitized patients awaiting kidney transplantation in China completed primary follow-up for all enrolled subjects.
The company said it plans to submit a new drug application to China’s National Medical Products Administration.
No clinical results were reported in the announcement, and no future presentation of results was specified.
KJ103 is described as a recombinant IgG-degrading enzyme intended to clear pre-existing HLA antibodies and reduce the risk of hyperacute rejection.
The Phase III trial began in August 2025 under registration CTR20252973, and KJ103 received Breakthrough Therapy Designation from the NMPA in November 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12066154), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622049942?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622049942","market":"nz","top_or_hot":-1,"title":"Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Shanghai Bao Pharmaceuticals said the Phase III trial of KJ103 as desensitization therapy for highly sensitized patients awaiting kidney transplantation in China completed primary follow-up for all enrolled subjects.\n        </li>\n<li>\n          The company said it plans to submit a new drug application to China’s National Medical Products Administration.\n        </li>\n<li>\n          No clinical results were reported in the announcement, and no future presentation of results was specified.\n        </li>\n<li>\n          KJ103 is described as a recombinant IgG-degrading enzyme intended to clear pre-existing HLA antibodies and reduce the risk of hyperacute rejection.\n        </li>\n<li>\n          The Phase III trial began in August 2025 under registration CTR20252973, and KJ103 received Breakthrough Therapy Designation from the NMPA in November 2024.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12066154), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 12:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Shanghai Bao Pharmaceuticals said the Phase III trial of KJ103 as desensitization therapy for highly sensitized patients awaiting kidney transplantation in China completed primary follow-up for all enrolled subjects.\n        </li>\n<li>\n          The company said it plans to submit a new drug application to China’s National Medical Products Administration.\n        </li>\n<li>\n          No clinical results were reported in the announcement, and no future presentation of results was specified.\n        </li>\n<li>\n          KJ103 is described as a recombinant IgG-degrading enzyme intended to clear pre-existing HLA antibodies and reduce the risk of hyperacute rejection.\n        </li>\n<li>\n          The Phase III trial began in August 2025 under registration CTR20252973, and KJ103 received Breakthrough Therapy Designation from the NMPA in November 2024.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12066154), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4LKWsy:1","article_id":"2622049942","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622049942","pubTimestamp":1774412444,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA. Shanghai Bao Pharmaceuticals said the Phase III trial of KJ103 as desensitization therapy for highly sensitized patients awaiting kidney transplantation in China completed primary follow-up for all enrolled subjects.The company said it plans to submit a new drug application to China’s National Medical Products Administration.No clinical results were reported in the announcement, and no future presentation of results was specified.KJ103 is described as a recombinant IgG-degrading enzyme intended to clear pre-existing HLA antibodies and reduce the risk of hyperacute rejection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B","BK1161":"生物科技"},"translate_title":"上海宝股份上涨；KJ103 III期肾移植脱敏试验完成主要随访，计划向中国NMPA提交NDA","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":0.9},"content_text":"Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA\n    \n\n\n          Shanghai Bao Pharmaceuticals said the Phase III trial of KJ103 as desensitization therapy for highly sensitized patients awaiting kidney transplantation in China completed primary follow-up for all enrolled subjects.\n        \n\n          The company said it plans to submit a new drug application to China’s National Medical Products Administration.\n        \n\n          No clinical results were reported in the announcement, and no future presentation of results was specified.\n        \n\n          KJ103 is described as a recombinant IgG-degrading enzyme intended to clear pre-existing HLA antibodies and reduce the risk of hyperacute rejection.\n        \n\n          The Phase III trial began in August 2025 under registration CTR20252973, and KJ103 received Breakthrough Therapy Designation from the NMPA in November 2024.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12066154), on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622049942","isCrawlerRequest":true}